Modi acted as if he himself handled lunar mission; he brought bad luck to ISRO: HDK

Bengaluru, Jan 5: Former Deputy Chief Minister G Parameshwara has said the Karnataka Congress has unanimously decided to appeal to the party high command regarding the appointment of KPCC President and Congress Legislature Party (CLP) leader in the state.

Speaking to reporters, the Congress leader said, "We have decided to gather the opinion of senior leaders regarding the selection of Karnataka Pradesh Congress Committee (KPCC) president and opposition leaders. We will appeal to the high command regarding the same. The party will decide its next course of action."

He made these remarks after a meeting of senior party leaders was held at Parameshwara's residence here on Saturday.

Adding that the Congress leaders discussed the current political scenario in the state, Parameshwara said: "We held a meeting to reiterate that we are not confused and we all are together."

"There has been no personal discussion on who should be the president," he said.

Earlier, KPCC president Dinesh Gundu Rao and former Chief Minister Siddaramaiah had tendered resignation from their respective posts owning moral responsibility for the party's poor performance in the recent by-polls.

Bengaluru, May 13: 26 new covid-19 cases have been reported in Karnataka taking the total cases to 951. This includes 32 COVID deaths, one non-COVID death and 442 discharges.

The new cases include eleven cases from Bidar - all of whom are from the containment zone - , four from Hassan, two each from Davangere, Kalaburgi, Vijayapura and Uttara Kannada and one each from Bengaluru Urban, Ballari and Dakshina Kannada.

All the cases reported in Hassan and Vijayapura are with a travel history to Mumbai. In Bengaluru Urban, a nurse from a designated COVID hospital who was under quarantine has tested positive.

32nd death

The latest death reported was that of a 60-year-old man in Kalaburgi district. The deceased man from a containment zone was brought dead on May 11 to a designated hospital in Kalaburagi, and he has tested positive for COVID-19, it said.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.